This article was originally published in The Gray Sheet
Board of directors has extended expiration date of outstanding warrants by one year, to June 19, 1994. Each warrant issued in Staodyn's 1991 financing entitles the holder to purchase one share of common stock at $8.50. The terms of the warrants will remain unchanged, according to an April 2 release announcing the extension. Staodyn had previously said that it might not extend the warrants ("The Gray Sheet" March 22, p. 21).
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.